Adrenomed AG products

Model Adrecizumab - Adrecizumab (HAM8101; INN: enibarcimab) - Clinical-Stage, First-In-Class Drug

The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular integrity.